Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat.com reports.

Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates ...

Avalo Therapeutics stock opened at $7.31 on Friday. The firm’s fifty day moving average price is $7.60 and its two-hundred day moving average price is $9.27. Avalo Therapeutics has a 1-year low ...

Avalo, a Durham startup using artificial intelligence to help develop climate-resistant crops, has secured $11 million in a Series A investment round.

WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation ...

As of March 20, 2025, the average one-year price target for Avalo Therapeutics is $33.66/share. The forecasts range from a low of $18.18 to a high of $50.40. The average price target represents an ...

On Monday, Stifel analysts began coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX), assigning the biopharmaceutical company a Buy rating and setting a price target of $36.00. According to ...

WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today ...

and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today ...